Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00297180 · ClinicalTrials.gov registry record · Phase 2
Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks
A Phase 2 study of Obesity, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 3
- Study locations
NCT00297180 is a Phase 2 study of Obesity that has completed, run by GlaxoSmithKline. The registered enrollment target is 136 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00297180, a Phase 2 study of Obesity, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 3
- Study locations
Study Summary
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
Conditions Studied
Interventions
- DRUG GW869682
Study Locations (3)
Florida
- GSK Investigational Site - Daytona Beach
Louisiana
- GSK Investigational Site - Baton Rouge
Oregon
- GSK Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00297180
The ClinicalTrials.gov registry entry for NCT00297180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which GW869682 is the first listed.
NCT00297180 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Louisiana, Oregon.
Frequently Asked Questions
What is clinical trial NCT00297180 about?
NCT00297180 is a clinical study titled "Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks". GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
What is the current status of trial NCT00297180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2006-01. Estimated completion is 2006-09.
What conditions does trial NCT00297180 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT00297180?
The interventions under investigation include: GW869682 (DRUG).
Who is sponsoring clinical trial NCT00297180?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00297180 being conducted?
This trial has 3 study locations across Florida, Louisiana, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.